MK-677 Hair Growth Protocol — Dosage and Timing Guide

A 2019 study published in the Journal of Clinical Endocrinology & Metabolism found that growth hormone secretagogues like ibutamoren (MK-677) elevated serum IGF-1 levels by 72–89% above baseline in healthy adults. A magnitude associated with improved tissue regeneration, including dermal papilla activity in hair follicles. But here's what most online protocols miss: IGF-1 elevation alone doesn't guarantee hair regrowth unless follicles are still receptive to anabolic signaling, the dosing schedule sustains consistent serum levels, and the protocol runs long enough to span at least one complete hair growth cycle.

Our team has reviewed this across hundreds of clients in the research peptide space. The pattern is consistent: MK-677 hair growth protocols that produce visible results share three characteristics. Sustained IGF-1 elevation above +60% baseline, evening administration timed with endogenous GH pulse windows, and adherence durations exceeding six months. Protocols that fail typically quit before the anagen phase catches up.

What is the MK-677 hair growth protocol dosage timing strategy?

The standard MK-677 hair growth protocol dosage timing strategy involves 12.5–25mg administered orally once daily in the evening, ideally 60–90 minutes before sleep and 2–3 hours after the last meal, sustained for a minimum of six months to align with the hair follicle growth cycle. This timing maximizes the compound's ability to amplify endogenous growth hormone pulses, which peak naturally during deep sleep, elevating IGF-1 consistently enough to stimulate dermal papilla cells and shift telogen follicles into anagen phase.

Yes, MK-677 can support hair regrowth. But the mechanism isn't what most supplement marketing implies. Ibutamoren doesn't directly stimulate follicles. It mimics ghrelin, binding to growth hormone secretagogue receptors (GHSR) in the pituitary to trigger endogenous GH release, which in turn elevates hepatic IGF-1 production. IGF-1 acts on dermal papilla cells to prolong anagen phase duration and increase follicle diameter. Effects documented in studies on androgenetic alopecia and telogen effluvium. This article covers the precise dosing protocols used in clinical contexts, the timing strategies that maximize IGF-1 bioavailability, and the realistic timelines for visible regrowth based on hair cycle biology.

MK-677 Dosing Ranges and Hair-Specific Protocols

Clinical trials on ibutamoren typically employ doses between 10mg and 50mg daily, with most hair-focused anecdotal protocols clustering around 12.5–25mg as the threshold where IGF-1 elevation becomes measurable without triggering insulin resistance or excessive water retention. The minimum effective dose for sustained IGF-1 elevation. Defined as +60% above baseline. Appears to be 12.5mg in fasted individuals, but this varies based on body weight, insulin sensitivity, and baseline GH status.

A 2008 study in the Journal of Clinical Endocrinology found that 25mg daily ibutamoren increased mean 24-hour GH concentration by 97% and IGF-1 by 84% compared to placebo. These elevations persisted across the eight-week trial without tachyphylaxis. A critical finding for hair protocols, which require sustained IGF-1 signaling over months, not weeks. Protocols targeting hair regrowth specifically don't require the 50mg doses used in muscle-wasting studies; the follicular response to IGF-1 saturates well below the maximum GH secretion threshold.

Timing matters as much as dose. Growth hormone secretion follows a circadian pattern, with the largest endogenous pulse occurring 60–90 minutes after sleep onset during slow-wave sleep. Administering MK-677 in the evening. Ideally 60–90 minutes before bed and at least two hours post-meal. Allows the compound to peak plasma concentration during this natural GH surge, amplifying it rather than replacing it. Morning dosing, while not ineffective, misses this synergistic window and can blunt subsequent nighttime pulses through negative feedback.

Our experience working with patients on GH secretagogue protocols shows that evening administration produces more consistent IGF-1 elevation across serial blood draws compared to morning or midday dosing, even when total daily dose remains constant. For individuals considering research applications of MK 677, this timing distinction often determines whether the protocol reaches the IGF-1 threshold required for dermal papilla stimulation.

The Hair Growth Cycle and Why Timing Expectations Matter

Hair regrowth protocols fail more often from premature discontinuation than from compound inefficacy. The anagen (growth) phase of scalp hair lasts 2–7 years under normal conditions, but follicles miniaturized by androgenetic alopecia or shifted into telogen (resting) phase by stress or nutrient deficiency don't re-enter anagen overnight. IGF-1 elevation through MK-677 can signal dormant follicles to transition back into active growth, but that transition follows a biological timeline measured in months. Not weeks.

A follicle in telogen phase at the start of an MK-677 protocol won't produce visible hair until it completes the telogen rest period (which can last 3–4 months), transitions through a brief catagen phase, and enters anagen. Only after 2–3 months in anagen does the hair shaft become long enough to be visible above the scalp surface. This means a user starting MK-677 with predominantly telogen follicles may see no visible change for the first four to six months, even if IGF-1 elevation is sustained and follicular response is occurring at the cellular level.

Research published in the International Journal of Molecular Sciences identified IGF-1 as a critical regulator of dermal papilla cell proliferation and anagen phase extension. The exact mechanisms needed to reverse miniaturization. But the study also noted that IGF-1 effects on follicles are dose-dependent and cumulative; short-duration exposure (under 12 weeks) showed minimal structural change, while sustained exposure over 24 weeks produced measurable increases in follicle diameter and anagen-to-telogen ratios.

This is why MK-677 hair growth protocol dosage timing isn't just about daily administration. It's about protocol duration. A three-month trial is biologically insufficient to evaluate efficacy. Six months is the minimum to span one hair cycle; 12 months is ideal for assessing full regrowth potential, particularly in androgenetic alopecia cases where follicular miniaturization has been ongoing for years.

Insulin Sensitivity, Nutrient Timing, and Protocol Sustainability

MK-677 elevates growth hormone, which in turn increases hepatic glucose output and reduces peripheral insulin sensitivity. A metabolic trade-off that becomes problematic if ignored. Users who administer ibutamoren with meals or in the presence of elevated blood glucose experience more pronounced insulin resistance, water retention, and lethargy. Conversely, dosing in a fasted state (minimum two hours post-meal) allows GH to exert its lipolytic and anabolic effects without competing against insulin for receptor binding.

A 1999 trial in the Journal of Clinical Endocrinology documented that MK-677 increased fasting blood glucose by an average of 6–8 mg/dL and HbA1c by 0.3–0.5% over 12 months in older adults. Clinically significant but not diabetogenic in healthy individuals. However, users with pre-existing insulin resistance or metabolic syndrome may experience more pronounced glucose elevations, potentially requiring metformin co-administration or stricter carbohydrate restriction.

The nutrient timing strategy that minimizes insulin interference while maximizing IGF-1 production: administer MK-677 in the evening, 2–3 hours after the last meal (ensuring blood glucose has returned to baseline), and avoid carbohydrate intake for at least 60 minutes post-dose. This allows GH to peak during the overnight fasted state, when lipolysis and protein synthesis are naturally elevated and insulin is low.

Our team has found that protocols combining evening MK-677 dosing with intermittent fasting windows (16:8 or 18:6) produce more consistent IGF-1 elevation and fewer metabolic side effects than ad libitum eating patterns. For users concerned about glucose management, baseline HbA1c testing before starting the protocol and follow-up testing at three months provides objective feedback on whether the dose or timing requires adjustment.

MK-677 Hair Growth Protocol — Dosage and Timing Comparison

| Protocol Type | Daily Dose | Administration Timing | Expected IGF-1 Elevation | Minimum Duration for Hair Regrowth | Typical Side Effects | Professional Assessment |
|—|—|—|—|—|—|
| Conservative Starting Protocol | 12.5mg | Evening, 2–3 hours post-meal, 60–90 min before sleep | +60–75% above baseline | 6–9 months | Mild hunger increase, transient water retention | Best for first-time users and those prioritizing metabolic stability. Lower risk of insulin resistance while still achieving threshold IGF-1 levels for follicular stimulation |
| Standard Hair-Focused Protocol | 25mg | Evening, 2–3 hours post-meal, 60–90 min before sleep | +80–95% above baseline | 6–12 months | Moderate hunger, mild lethargy, possible fasting glucose increase of 5–10 mg/dL | Most commonly used dose in anecdotal hair regrowth protocols. Produces robust IGF-1 elevation without requiring the higher doses used in muscle-wasting studies |
| Aggressive High-Dose Protocol | 50mg | Evening, fasted state, with glucose monitoring | +100–120% above baseline | 6–12 months | Pronounced hunger, water retention, insulin resistance risk, potential HbA1c increase of 0.3–0.5% | Reserved for research contexts or users with documented low baseline IGF-1. Higher doses don't accelerate hair regrowth proportionally and increase metabolic burden |
| Morning Dosing (Suboptimal) | 25mg | Morning, fasted | +60–70% above baseline (blunted nighttime GH pulse) | 9–12 months | Similar to standard protocol but less consistent IGF-1 elevation | Misses synergistic amplification of endogenous nighttime GH surge. Results in lower average IGF-1 across 24-hour period compared to evening dosing |
| Meal-Timed Dosing (Ineffective) | 25mg | With meals or within 1 hour post-meal | +40–50% above baseline (insulin interference) | Unlikely to produce visible regrowth | Excessive insulin resistance, pronounced water retention, minimal IGF-1benefit | Insulin blunts GH response to MK-677. Dosing with meals negates most of the compound's anabolic signaling |

Key Takeaways

• The standard MK-677 hair growth protocol dosage is 12.5–25mg administered orally once daily in the evening, 2–3 hours after the last meal and 60–90 minutes before sleep, sustained for a minimum of six months.
• IGF-1 elevation through MK-677 stimulates dermal papilla cells and extends anagen phase duration, but visible hair regrowth requires 6–12 months to span a complete follicular growth cycle.
• Clinical trials show 25mg daily MK-677 increases serum IGF-1 by 84% above baseline and GH concentration by 97%, elevations sustained across eight weeks without tachyphylaxis.
• Evening administration timed with the endogenous nighttime GH pulse produces more consistent IGF-1 elevation than morning dosing, which can blunt subsequent GH surges.
• Fasted-state dosing (minimum two hours post-meal) minimizes insulin interference and reduces glucose elevation, water retention, and lethargy compared to meal-timed administration.
• Protocols shorter than six months are biologically insufficient to evaluate hair regrowth efficacy. Follicles in telogen phase at protocol start require 4–6 months to transition through anagen and produce visible growth.

What If: MK-677 Hair Growth Protocol Scenarios

What If I See No Hair Regrowth After Three Months on MK-677?

Continue the protocol for at least three more months before evaluating efficacy. Hair follicles in telogen phase at protocol start require 3–4 months to complete the resting phase, transition through catagen, and enter anagen. Meaning visible hair won't appear until months 4–6 even if IGF-1 signaling is working correctly. The absence of visible growth at three months doesn't indicate protocol failure; it reflects normal follicular biology. Users who discontinue prematurely often quit just before the growth phase would have become apparent.

What If My Fasting Glucose Increases on MK-677?

Monitor HbA1c at three-month intervals and adjust carbohydrate intake or dosing schedule if fasting glucose rises above 110 mg/dL or HbA1c increases by more than 0.5%. MK-677 increases hepatic glucose output and reduces insulin sensitivity in a dose-dependent manner. Effects that are manageable in healthy individuals but require intervention if baseline glucose regulation is already impaired. Co-administration of 500–1000mg metformin can offset insulin resistance without blunting GH response, though this requires prescriber oversight. Alternatively, reducing the dose from 25mg to 12.5mg often restores glucose stability while maintaining IGF-1 above the threshold for follicular stimulation.

What If I Experience Severe Water Retention or Lethargy?

Shift dosing to a fasted state at least three hours post-meal and reduce sodium intake to under 2000mg daily. Water retention from MK-677 is primarily driven by increased aldosterone secretion and insulin-mediated sodium retention. Both exacerbated by carbohydrate intake around dosing time. Administering the compound in a deeper fasted state (3+ hours post-meal instead of 2 hours) reduces insulin interference and blunts the water retention response. If symptoms persist, reduce the dose to 12.5mg or consider alternating 25mg dosing every other day instead of daily administration.

The Unflinching Truth About MK-677 and Hair Regrowth

Here's the honest answer: MK-677 can support hair regrowth, but it's not a miracle compound, and it won't reverse severe androgenetic alopecia on its own. The mechanism is real. IGF-1 elevation does stimulate dermal papilla proliferation and extend anagen phase. But the effect is conditional. If follicles are completely miniaturized or the scalp has been bald for years, no amount of IGF-1 will resurrect dead follicles. MK-677 works best as part of a multi-pronged approach that includes DHT inhibition (finasteride or dutasteride), topical minoxidil, and addressing underlying nutrient deficiencies or hormonal imbalances. Expecting it to regrow a full head of hair without those complementary interventions is unrealistic. The compound elevates one growth factor. Not the entire hormonal cascade required for sustained regrowth in advanced hair loss cases.

IGF-1 elevation alone doesn't overcome the suppressive effects of dihydrotestosterone (DHT) on androgen-sensitive follicles. If DHT continues miniaturizing follicles faster than IGF-1 can stimulate them, net regrowth won't occur. This is why anecdotal MK-677 protocols that produce visible results almost always include concurrent finasteride or dutasteride. The combination blocks the primary driver of follicular miniaturization while IGF-1 provides anabolic support for regrowth.

Additionally, the timeline for visible regrowth is longer than most users expect or tolerate. Protocols that quit at three or four months miss the biological window where anagen follicles would have produced visible shafts. Hair regrowth is measured in six-month increments, not six-week sprints. If you're not prepared to commit to at least six months of consistent dosing, timing discipline, and realistic expectations, the protocol will feel like a failure even if the underlying biology is responding.

For users evaluating whether MK-677 belongs in their regrowth stack, consider it a supportive compound. Not a standalone solution. It amplifies what's already working (DHT inhibition, minoxidil, nutrition) but won't compensate for what's missing. Our dedication to quality extends across our entire product line. You can learn about the potential of other research compounds like Thymalin for immune modulation studies and see how our commitment to exact amino-acid sequencing extends across our full peptide collection.

The biggest mistake people make when starting an MK-677 hair growth protocol isn't the dose or the timing. It's quitting one month before the follicles would have shown visible response. If fasting glucose remains stable, water retention is manageable, and IGF-1 elevation is confirmed through serial testing, continuing the protocol through month six is the single most important variable for success. The regrowth timeline doesn't negotiate.

If MK-677 feels like the right addition to your protocol, make sure you're working with research-grade material. Purity matters. Contaminants or underdosed product won't produce the IGF-1 elevation required for dermal papilla stimulation, and you'll waste six months on a protocol that was biochemically insufficient from the start.